These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 36717184)

  • 1. Generation of novel oncolytic vaccinia virus with improved intravenous efficacy through protection against complement-mediated lysis and evasion of neutralization by vaccinia virus-specific antibodies.
    Lee N; Jeon YH; Yoo J; Shin SK; Lee S; Park MJ; Jung BJ; Hong YK; Lee DS; Oh K
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36717184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans.
    Kim MK; Breitbach CJ; Moon A; Heo J; Lee YK; Cho M; Lee JW; Kim SG; Kang DH; Bell JC; Park BH; Kirn DH; Hwang TH
    Sci Transl Med; 2013 May; 5(185):185ra63. PubMed ID: 23677592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
    Deng L; Fan J; Guo M; Huang B
    Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.
    Park SH; Breitbach CJ; Lee J; Park JO; Lim HY; Kang WK; Moon A; Mun JH; Sommermann EM; Maruri Avidal L; Patt R; Pelusio A; Burke J; Hwang TH; Kirn D; Park YS
    Mol Ther; 2015 Sep; 23(9):1532-40. PubMed ID: 26073886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Oncolytic Vaccinia Virus Harboring the Human IFNB1 and CES2 Transgenes.
    Cho E; Islam SMBU; Jiang F; Park JE; Lee B; Kim ND; Hwang TH
    Cancer Res Treat; 2020 Jan; 52(1):309-319. PubMed ID: 31401821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.
    Kirn DH; Wang Y; Le Boeuf F; Bell J; Thorne SH
    PLoS Med; 2007 Dec; 4(12):e353. PubMed ID: 18162040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers.
    Du T; Shi G; Li YM; Zhang JF; Tian HW; Wei YQ; Deng H; Yu DC
    Cancer Gene Ther; 2014 Aug; 21(8):340-8. PubMed ID: 25034886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia.
    Wang W; Liu S; Dai P; Yang N; Wang Y; Giese RA; Merghoub T; Wolchok J; Deng L
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF.
    Kim JH; Oh JY; Park BH; Lee DE; Kim JS; Park HE; Roh MS; Je JE; Yoon JH; Thorne SH; Kirn D; Hwang TH
    Mol Ther; 2006 Sep; 14(3):361-70. PubMed ID: 16905462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma.
    Lun X; Chan J; Zhou H; Sun B; Kelly JJ; Stechishin OO; Bell JC; Parato K; Hu K; Vaillant D; Wang J; Liu TC; Breitbach C; Kirn D; Senger DL; Forsyth PA
    Mol Ther; 2010 Nov; 18(11):1927-36. PubMed ID: 20808290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques.
    Evgin L; Acuna SA; Tanese de Souza C; Marguerie M; Lemay CG; Ilkow CS; Findlay CS; Falls T; Parato KA; Hanwell D; Goldstein A; Lopez R; Lafrance S; Breitbach CJ; Kirn D; Atkins H; Auer RC; Thurman JM; Stahl GL; Lambris JD; Bell JC; McCart JA
    Mol Ther; 2015 Jun; 23(6):1066-1076. PubMed ID: 25807289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.
    Heo J; Reid T; Ruo L; Breitbach CJ; Rose S; Bloomston M; Cho M; Lim HY; Chung HC; Kim CW; Burke J; Lencioni R; Hickman T; Moon A; Lee YS; Kim MK; Daneshmand M; Dubois K; Longpre L; Ngo M; Rooney C; Bell JC; Rhee BG; Patt R; Hwang TH; Kirn DH
    Nat Med; 2013 Mar; 19(3):329-36. PubMed ID: 23396206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy.
    Kochneva G; Sivolobova G; Tkacheva A; Grazhdantseva A; Troitskaya O; Nushtaeva A; Tkachenko A; Kuligina E; Richter V; Koval O
    Oncotarget; 2016 Nov; 7(45):74171-74188. PubMed ID: 27708236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy.
    Shi Z; Liu B; Huang C; Xie W; Cen Y; Chen L; Liang M
    Biochem Biophys Res Commun; 2021 Jun; 559():176-182. PubMed ID: 33945995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
    Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
    Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
    Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
    Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
    [No Abstract]   [Full Text] [Related]  

  • 17. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
    Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
    EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy.
    de Vries CR; Monken CE; Lattime EC
    Cancer Gene Ther; 2015 Apr; 22(3):154-62. PubMed ID: 25633483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic vaccinia virus for the treatment of cancer.
    Guse K; Cerullo V; Hemminki A
    Expert Opin Biol Ther; 2011 May; 11(5):595-608. PubMed ID: 21338330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope.
    Vanderplasschen A; Mathew E; Hollinshead M; Sim RB; Smith GL
    Proc Natl Acad Sci U S A; 1998 Jun; 95(13):7544-9. PubMed ID: 9636186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.